STOCK TITAN

Shattuck Labs (STTK) S-3 Filings

STTK NASDAQ

Here are the S-3 shelf registrations from Shattuck Labs, Inc. (STTK) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

An S-3 covers the shelf registration that lets an established company sell over time, so if you follow STTK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STTK filings page.

Rhea-AI Summary

Shattuck Labs, Inc. has filed a shelf registration to offer up to $200,000,000 in aggregate of common stock, preferred stock, debt securities, warrants and units from time to time. Each offering will have its own prospectus supplement detailing specific terms, pricing and the method of sale, which may include underwritten offerings, direct sales or at-the-market transactions on The Nasdaq Global Select Market under the symbol STTK. The company develops potential treatments for inflammatory and immune-mediated diseases, led by its SL-325 antibody program. Net proceeds from future offerings are expected to fund ongoing and planned clinical trials, development of additional product candidates, and general corporate and working capital needs, with possible use for licensing or acquisitions.